Advaxis seeks FDA approval to begin first-in-human trial of ADXS-HER2
The trial is scheduled to start in the first quarter of 2015. It is designed to evaluate the safety and tolerability of ADXS-HER2 in patients diagnosed with metastatic
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.
These high-risk patients typically do not respond well to standard therapies. These results were published in The Lancet Oncology. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and
The two parties have also entered into an exclusive license agreement that allows BMS to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration. Bristol-Myers Squibb